International Congress on the Future of Breast Cancer West | Conference

Understanding the Role of pCR in Early-Stage TNBC Opens Doors for Tailored Treatment

July 30th 2022

As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.

How Low Can We Go? Metastatic Breast Cancer Enters a New Era of HER2 Classification

July 30th 2022

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

Chemotherapy Benefit May Stem From Ovarian Function Suppression in Premenopausal HR+/HER2- Breast Cancer

July 30th 2022

Nicholas P. McAndrew, MD, MSCE, discusses considerations to take when examining the relationship between chemotherapy, ovarian function suppression, and treatment benefits experienced by patients with hormone receptor–positive, HER2-negative breast cancer.

HER2-Directed Treatment Escalation or De-escalation Necessitates Careful Consideration in HER2+ Breast Cancer

July 29th 2022

Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.

Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast Cancer

July 29th 2022

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Dr. McAndrew on Chemotherapy Vs Ovarian Function Suppression in HR+ Breast Cancer

July 29th 2022

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

Oral SERDs Could Fulfill Unmet Need in ESR1-Mutant, ER-Positive Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

Dr. Pegram on Considerations for Treatment Selection in HER2+ Breast Cancer

August 4th 2021

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

CDK4/6 Inhibitors Improve OS, but Sequencing Strategies Continue to Form in HR+/HER2- Breast Cancer

August 2nd 2021

Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.

Pegram Points to Progress, Ongoing Efforts in Advanced HER2+ Breast Cancer

August 2nd 2021

Physicians treating patients with HER2-positive metastatic breast cancer have had their share of wins with treatment advances in the past few years.

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

July 30th 2021

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

New Focus Needed on Preventing Brain Metastases in Early Breast Cancer

August 1st 2020

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

Sparano Shares Progress Made in the Molecular Guided Management of Breast Cancer

July 31st 2020

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy.

Deciphering DNA Repair Deficiency in Breast Cancer

July 31st 2020

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

Dr. O’Regan on Biomarkers of Response to CDK4/6 Inhibitors in Breast Cancer

July 31st 2020

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Dr. Tripathy on Genomically Guided Therapy in Breast Cancer

July 31st 2020

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Dr. Goldstein on Mechanisms of Resistance to Endocrine Therapy

July 19th 2014

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

July 18th 2014

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic Agents

July 17th 2014

Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.